BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld Science
  • BioWorld Asia
  • Data Snapshots
    • Biopharma
    • Medical technology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Med-tech outlook 2026
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • Bioworld 2025 review
    • BioWorld MedTech 2025 review
    • BioWorld Science 2025 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Monday, March 23, 2026
Breaking News: Trump administration impacts continue to roil the life sciences sectorBreaking News: Trump administration impacts continue to roil the life sciences sectorBreaking News: Trump administration impacts continue to roil the life sciences sector
Home » Topics » BioWorld Science

BioWorld Science
BioWorld Science RSS Feed RSS

Neurology/psychiatric

Emcure Pharmaceuticals reports HDAC inhibitors

Feb. 23, 2026
Work at Emcure Pharmaceuticals Ltd. and Peptris Technologies has led to the identification of new fused bicyclic heterocyclic derivatives acting as histone deacetylase (HDAC) inhibitors.
Read More
Cancer

Bayer identifies SOS1 inhibitors for cancer

Feb. 23, 2026
Bayer AG has synthesized new son of sevenless homolog 1 (SOS1) inhibitors reported to useful for the treatment of cancer.
Read More
Colorectal cancer 3D illustration
Immuno-oncology

L. monocytogenes vaccine enhances immunotherapy efficacy in CRC

Feb. 23, 2026
No Comments
In a recent study, researchers from Stony Brook University Renaissance School of Medicine and Cold Spring Harbor Laboratory investigated whether in vivo targeting of gastrointestinal tissues via foodborne delivery of Lm-based cancer vaccines could control tumor growth in murine models of colorectal cancer.
Read More
Eye and DNA
Cancer

CRISPR-Cas13d-mediated targeting of RasGRP3 shows selective anticancer effects in uveal melanoma

Feb. 23, 2026
No Comments
A new study by researchers at Stanford University and collaborating institutions aimed to investigate the safety and efficiency of lipid nanoparticle-mediated Cas13d mRNA delivery to uveal melanoma cells.
Read More
Liver illustration
Endocrine/metabolic

C/EBPβ targeting by GalNAc-conjugated siRNA restores liver function in MASLD

Feb. 23, 2026
No Comments
Researchers from Imperial College London and collaborators further investigated C/EBPβ as a target for MASLD and evaluated the efficacy of a C/EBPβ-targeted siRNA approach to reverse metabolic dysfunction and restore liver function in high-fat-diet-induced steatosis, which can be precursor to MASH and hepatocellular carcinoma.
Read More
Cholesterol plaque in artery
Endocrine/metabolic

Vector-mediated LDLR/TF expression in muscle reduces atherosclerosis in LDLR-deficient mice

Feb. 23, 2026
No Comments
In previous work, researchers from CEINGE (Naples, Italy) and collaborating institutions developed an alternative gene therapy strategy based on the expression of a secreted fusion protein, including the extracellular portion of the human LDLR for LDL binding, linked to rabbit transferrin (TF), targeting the transferrin receptor (TFr), resulting in internalization and uptake of LDL particles. They have now published more recent work to further improve the efficacy and safety of this strategy.
Read More
Bispecific antibodies with heavy chain in green and pink, light chain in blue and yellow
Immuno-oncology

First-in-class LTβR x EDB bispecific antibody overcomes checkpoint resistance

Feb. 23, 2026
No Comments
Researchers from Agni Bio Inc. reported the preclinical profile of AGB-201, a bispecific antibody designed to simultaneously target EDB and LTβR, while minimizing unwanted immune activation.
Read More
T cells
Immuno-oncology

Zelluna’s ZI-MA4-1 gains UK CTA clearance for solid tumors

Feb. 23, 2026
No Comments
Zelluna ASA has received approvals from the U.K.’s Medicines and Healthcare products Regulatory Agency (MHRA) and research ethics committee for its clinical trial application (CTA) for ZI-MA4-1, Zelluna’s lead T-cell receptor-based natural killer (TCR-NK) product candidate.
Read More
Ocular

New mouse model of Sjögren’s disease-associated dry eye

Feb. 23, 2026
No Comments
Scientists based at Capital Medical University (Beijing, China) have designed a lacrimal gland-specific autoimmune model that recapitulates the main features of Sjögren’s disease-associated dry eye.
Read More
Malaria-infected red blood cells
Infection

New malaria resistance variant identified

Feb. 23, 2026
By Xavier Bofill Bruna
No Comments
Researchers from the University of Sassari (Italy) and their collaborators have recently published findings from their research focused on the impact of one allelic variant in the CCND3 gene, encoding cyclin D3, on blood cell traits and resistance to malaria.
Read More
Previous 1 2 … 22 23 24 25 26 27 28 29 30 … 18020 18021 Next

Popular Stories

  • Today's news in brief

    BioWorld
  • Art concept for targeting the brain

    Precision psychiatry beyond, or before, biomarkers

    BioWorld
    There is broad agreement that psychiatric diagnoses in their current form are not reflective of any underlying biology, and that this is one of the things...
  • MRI image brain on black background

    ADPD 2026: Can we prevent dementia? Scientists quantify it

    BioWorld
    Neurodegenerative disease and cognitive decline cannot be explained by a single process. Beta-amyloid plaques, hyperphosphorylated tau, alpha-synuclein, activated...
  • Illustration of Alzheimer's disease in the brain

    ADPD 2026: Three inflection points to target Alzheimer’s disease

    BioWorld Science
    A new way of understanding Alzheimer’s disease, based on biological inflection points that mark decisive moments in the progression of the disorder, could change...
  • First-in-class POLG activator restores mtDNA across mutations

    BioWorld Science
    Researchers from Pretzel Therapeutics Inc. presented preclinical data of PX-578, a first-in-class POLG activator aimed at restoring mtDNA replication and...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Medical technology
    • Newco news
    • Opinion
    • Regulatory
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/metabolic
    • Immune
    • Infection
    • Neurology/psychiatric
    • NME Digest
    • Patents
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2026. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing